Active, not recruitingPHASE1, PHASE2NCT05222555
Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients
Studying Diffuse large B-cell lymphoma with chronic inflammation
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Incyte Corporation
- Principal Investigator
- Incyte Medical DirectorIncyte Corporation
- Intervention
- Tafasitamab(drug)
- Enrollment
- 53 target
- Eligibility
- 18-99 years · All sexes
- Timeline
- 2022 – 2027
Study locations (30)
- Morristown Memorial Hospital, Morristown, New Jersey, United States
- Texas Oncology-Baylor Charles A. Sammons Cancer Center - USOR, Dallas, Texas, United States
- Vista Oncology, Olympia, Washington, United States
- UK St. Pölten, Sankt Pölten, Lower Austria, Austria
- Klinikum Wels Grieskirchen, Wels, Upper Austria, Austria
- Universitatsklinikum Salzburg, Salzburg, Austria
- Fakultni nemocnice Brno, Brno, Czechia
- Fakultni nemocnice Ostrava, Ostrava, Czechia
- Fakultni nemocnice Kralovske Vinohrady, Prague, Czechia
- Vseobecna Fakultni Nemocnice V Praze, Prague, Czechia
- Fakultni nemocnice v Motole, Prague, Czechia
- Centre Hospitalier Universitaire Grenoble Alpes - Hopital Albert Michallon, Grenoble, Isère, France
- CHU Nantes, Nantes, Loire-Atlantique, France
- Centre Hospitalier Le Mans, Le Mans, Sarthe, France
- CHU de Poitiers, Poitiers, Vienne, France
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05222555 on ClinicalTrials.govOther trials for Diffuse large B-cell lymphoma with chronic inflammation
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGPHASE2NCT07538180Serplulimab, Chidamide, and Rituximab Followed by Sequential R-CHOP for Newly Diagnosed Elderly MYC/BCL2 Double-Expressor DLBCLSun Yat-sen University
- RECRUITINGNCT07070648Study on Predicting Response to Standard First-Line Treatment in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Using ctDNA Combined With PETFudan University
- RECRUITINGPHASE1, PHASE2NCT06829771Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell LymphomaChia Tai Tianqing Pharmaceutical Group Co., Ltd.
- RECRUITINGPHASE3NCT06717347A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)Merck Sharp & Dohme LLC
- RECRUITINGPHASE2NCT06687772CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma With Thiotepa-based Autologous Stem Cell TransplantWashington University School of Medicine
- RECRUITINGPHASE1, PHASE2NCT06760039Safety and Efficacy of R-CMOP Versus R-CHOP in the Initial Treatment of DLBCLSun Yat-sen University
- RECRUITINGPHASE2NCT06701357CR-CHOP+X in Previously Untreated DELRuijin Hospital
- RECRUITINGPHASE2NCT06664411Pola-ZR2P in Previously Untreated DLBCLNavy General Hospital, Beijing
See all trials for Diffuse large B-cell lymphoma with chronic inflammation →